Gates, others launch $500 million maternal, newborn health fund, bucking aid cuts trend
LONDON, April 29 (Reuters) - A group of philanthropies including the Gates Foundation has set up a fund backed with nearly $500 million to help save the lives of newborn babies and mothers in sub-Saharan Africa, standing out against a bleak global health funding landscape.
The Beginnings Fund was launched on Tuesday in Abu Dhabi, the home of another key backer - the United Arab Emirates' recently rebranded Mohamed Bin Zayed Foundation for Humanity.
The project has been in the works for at least a year. But its role has become more important as governments worldwide follow the U.S. in pulling back from international aid, its chief executive Alice Kang'ethe told Reuters in an interview.
'It is an opportune moment,' she said earlier this month, stressing that the fund aimed to work alongside African governments, experts and organizations rather than parachuting in experts or technologies, an approach she said differed from many traditional donor programmes.
The Beginnings Fund aims to save the lives of 300,000 mothers and newborn babies by 2030, and expand quality care for 34 million mothers and babies.
The partners also pledged $100 million in direct investments in maternal and child health, separate to the fund.
It plans to operate in Ethiopia, Ghana, Kenya, Malawi, Lesotho, Nigeria, Rwanda, Tanzania, Uganda, and Zimbabwe, focusing on low-cost interventions and personnel in high-burden hospitals. The work will track and target the key reasons babies and mothers die, including infection, severe bleeding for mothers, and respiratory distress for infants.
The world has made major progress in reducing newborn and maternal deaths, halving the neonatal mortality rate between 1990 and 2022. But that progress has stagnated or even reversed in nearly all regions in the last few years, according to the World Health Organization, which has warned that aid cuts could make this worse.
'Mothers and newborns should not be dying from causes we know how to prevent,' said Dr. Mekdes Daba, minister of health for Ethiopia, stressing that the majority of deaths are avoidable.
Kang'ethe said the Beginnings Fund, like other philanthropies, was getting calls to fill gaps in global aid funding, but remained focused on its long-term aim of changing the trajectory of mother and newborn survival.
The fund is also backed by the Children's Investment Fund Foundation, Delta Philanthropies and the ELMA Foundation, among others. It will be led from Nairobi, Kenya.
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Daily Mirror
2 days ago
- Daily Mirror
Man dies of rabies after dog bite as officials issue urgent 'stay calm' warning
Spanish health officials have called on the public to get rabies vaccinations should they find themselves in specific situations after a man died of the virus in Valencia Health authorities have issued an urgent public warning after a man bitten by a dog died from rabies in an "exceptional" case that has sparked panic. Spanish health officials said the unnamed man, 44, died in hospital after carrying his infection from the African nation of Ethiopia, where he was bitten by a dog. Rabies, which is almost always deadly once humans show symptoms, aside from a few isolated cases, is not common in Spain, and authorities have been forced to warn people not to worry after news of the infection was made public. People have been told to get vaccinated if they find themselves in specific circumstances following the man's nightmare experience. READ MORE: What is zoonosis? Worrying new disease development explained - and how it could cause next pandemic Spanish authorities said the 44-year-old contracted rabies from a dog bite during a trip to Ethiopia in July 2024, and was taken to a Valencia hospital in "very serious" condition before his death. The man, whose nationality has not been revealed, died today, nearly a year after initially contracting the infection and following a stay in intensive care. He was not vaccinated - the only possible way to prevent death from infection - following his trip to the country last year, prompting authorities to issue a public warning. Health officials said people should get a rabies vaccination if they are planning to travel or be in close contact with any animals that may be carrying the infection. The man was bitten on his right leg but failed to seek further attention after returning from Ethiopia when he cleaned the wound and finding he had recovered well. Analytical tests conducted in Spain confirmed a rabies positive case on May 29, and medics administered an anti-rabies immunoglobulin as he was admitted to hospital. The immunoglobulin is highly effective at preventing death from rabies, but only if it is administered by doctors soon after the potential infection. The victim's wife, the only contact at risk, was also given the rabies vaccine and immunoglobulin. Marciano Gómez, Spain's minister of health, stressed it was an "isolated" case, adding that rabies had been eradicated in Spain. The country is one of several - including nations like the UK, Japan, New Zealand and Australia - to declare themselves rabies free. Mr Gomez said: "It is transmitted by bites from infected animals in countries where it is not controlled and exceptionally by drops of saliva or a conjunctival ulcer." Health authorities confirmed that nothing else could have been done to save the man's life.
Reuters
3 days ago
- Reuters
Novo's Ozempic, Wegovy linked to rare cases of dangerous eye disorder, EMA says
June 6 (Reuters) - The European Medicines Agency's safety committee has concluded that the use of Novo Nordisk's ( opens new tab popular weight-loss drug Wegovy and its treatments for type 2 diabetes may cause rare occurrences of a potentially dangerous eye condition. Called non-arteritic anterior ischemic optic neuropathy (NAION), the condition may affect up to 1 in 10,000 people taking semaglutide, the active ingredient in Wegovy and Novo's diabetes drugs Ozempic and Rybelsus, the regulator said on Friday. The EMA, which started its review in December, said the use of the drugs is linked to about twofold increase in the risk of developing the condition compared to people not taking the medicine. NAION develops from insufficient blood flow to the optic nerve and causes sudden painless vision loss in one eye. It is the second most common cause of blindness due to optic nerve damage, after glaucoma. Studies have linked semaglutide to NAION in the past. But this is the first time a regulator has made the link. Semaglutide belongs to a class of drugs known as GLP-1 receptor agonists, which work by helping control blood sugar levels and triggering a feeling of fullness. A large study of nearly 350,000 diabetics published earlier this year had showed that the risk of developing NAION more than doubled after long-term use of semaglutide, compared to patients taking medicines from other classes. The EMA said it has reviewed all available data on NAION with semaglutide, including data from non-clinical studies, clinical trials and post-marketing surveillance. It has recommended the drugmaker to update prescribing information for medicines containing semaglutide to include NAION as a side effect with a frequency of "very rare". The U.S. Food and Drug Administration did not immediately respond to a Reuters request for comment.
Reuters
3 days ago
- Reuters
Health Rounds: Roche's Tecentriq reduces recurrence, deaths for certain colon cancer patients
June 6 (Reuters) - (This is an excerpt of the Health Rounds newsletter, where we present latest medical studies on Tuesdays and Thursdays. To receive the full newsletter in your inbox for free sign up here.) Adding Roche's (ROG.S), opens new tab immunotherapy drug Tecentriq to chemotherapy after surgery in certain patients whose colon cancer had spread to the lymph nodes led to a 50% reduction in cancer recurrence and death compared to chemotherapy alone, according to trial data presented at recent medical meeting. Patients in the study had tumors with a genetic defect known as deficient DNA mismatch repair, or dMMR. About 15% of colon cancer patients have dMMR tumors, which do not respond well to chemotherapy. "The findings from our study represent a major advance in the adjuvant treatment of dMMR stage 3 colon cancer and will now change the treatment for this type of cancer," study leader Dr. Frank Sinicrope of the Mayo Clinic in Rochester, Minnesota said in a statement. The data, opens new tab were presented at the ASCO meeting that concluded earlier this week. The trial enrolled 712 patients with dMMR stage 3 colon cancer that had been surgically removed and who had cancer cells in their lymph nodes. Half of the study participants received chemotherapy along with Tecentriq, which activates the immune system to attack and kill cancer cells, for six months, followed by the immunotherapy alone for another six months. The other half of the patients received chemotherapy for 12 months. The benefit of Tecentriq was seen even in the oldest patients and those at particularly high-risk. "It's extremely rewarding to be able to offer our patients a new treatment regimen that can reduce the risk of recurrence and improve their chances of survival," Sinicrope said. As patients recover after a minimally invasive heart procedure, they might be better off continuing to take a certain type of blood-thinning drug to help prevent a heart attack or stroke, instead of continuing with the traditional aspirin, a new study suggests. Early after percutaneous coronary intervention (PCI) - a procedure to prop open blocked arteries either after a heart attack, or to prevent one - patients often receive dual anti-clotting therapy with both a P2Y12 inhibitor such as clopidogrel, the generic version of Plavix, or AstraZeneca's (AZN.L), opens new tab Brilinta (ticagrelor), and aspirin. After several months, patients are usually switched from dual therapy to lifelong daily aspirin use. But pooled data looking at patients who took part in five earlier clinical trials found that continuing to prescribe the P2Y12 inhibitors and stopping the aspirin was associated with lower rates of death, heart attack and stroke compared with continuing the aspirin, with no increased risk of major bleeding, researchers reported in The BMJ, opens new tab. Overall, the trials involved 16,117 patients who received either a P2Y12 inhibitor or aspirin after completing dual therapy following PCI. After an average follow-up period of around 4 years, P2Y12 inhibitor therapy was associated with a 23% lower risk of a composite of heart-related death, heart attack, or stroke, compared with aspirin, with no significant difference in major bleeding. That translates into one prevented cardiovascular death, heart attack, or stroke for every 46 patients taking a P2Y12 inhibitor instead of aspirin after dual therapy. Overall, the findings suggest that P2Y12 inhibitor drugs should be preferred over aspirin 'due to reductions in major adverse cardiac and cerebrovascular events without increasing major bleeding in the medium term,' according to an editorial published with the study. But the editorial said that since patients are advised to continue the post-PCI therapy for life, large trials directly comparing the different strategies with longer follow up are needed. Some diabetes and weight-loss drugs from the class known as GLP-1 agonists were linked with a small but elevated risk for an age-related eye disease in patients with diabetes, according to a study published on Thursday in JAMA Ophthalmology, opens new tab. In 139,000 patients with diabetes, including 46,334 who had been using the GLP-1 drugs semaglutide or lixisenatide, researchers identified 181 new cases of neovascular age-related macular degeneration, also known as wet AMD. Wet AMD is a degenerative eye disease marked by the abnormal growth of blood vessels under the retina that leak fluid or blood and can lead to blindness. The risk of developing AMD during up to three years of follow-up was low, at 0.2% in GLP-1 users versus 0.1% in non-users. Still, the researchers point out, after accounting for patients' individual risk factors, the odds of AMD were doubled with at least six months of GLP-1 use and tripled in patients with the longest duration of use. Semaglutide is the active ingredient in the widely used Novo Nordisk ( opens new tab drugs Ozempic and Wegovy, while lixisenatide is the main ingredient in Sanofi's ( opens new tab discontinued Adlyxin. GLP-1 drugs have also been associated with higher risks for an eye condition known as nonarteritic anterior ischemic optic neuropathy, or NAION. Researchers did not have information about the dose, route of administration, or frequency of administration of the medications used in the study. Even with that information, the study could not have proved cause and effect. At least one earlier study with longer follow up reported that GLP-1 use was linked with a lower, rather than higher, risk for AMD. 'Our findings are not directly contradictory' with that earlier report, said study leader Dr. Reut Shor of the University of Toronto. 'Factors such as timing and duration of exposure, disease stage, and patient characteristics may all influence outcomes," Shor said. "Our results add another layer to the emerging understanding of this complex relationship and emphasize the need for further research to clarify these trends.' (To receive the full newsletter in your inbox for free sign up here)
